News

Cupron® Introduces Revolutionary, Cost-effective Antimicrobial Technology, Cupron Sinerji™

Cupron®, a renowned antimicrobial solutions provider – doing business as Cupron Performance Additives – is excited to announce the significant expansion of its offerings with the introduction of Cupron Sinerji™. This new adjuvant-enhanced platform offers superior antimicrobial efficacy across multiple substrates, all while maintaining an economical cost structure.

Cupron Sinerji incorporates adjuvants into the copper-based formulation, resulting in a custom, flexible technology engineered to harness synergistic effects to meet a wide range of product protection and antimicrobial performance objectives – from US EPA Treated Article Exemptions to unique and differentiated Public Health Claims.

Utilizing adjuvants, the technology delivers heightened efficacy against various organisms, improves color selection, and increases manufacturing yields. It offers an efficient and adaptable solution for numerous markets and applications, demonstrating its versatility and innovative potential across all polymers and organisms.

“The high prices of silver additives have previously compelled many brands to restrict their use in product manufacturing, subsequently diminishing the antimicrobial potency of the final products,” said Chris Andrews, CEO of Cupron Performances Additives. “However, Cupron Sinerji’s competitive cost to performance ratio is set to revolutionize traditional views on the value of antimicrobial solutions, introducing them to new applications that were previously considered cost-prohibitive.”

Cupron Sinerji has an attractive sustainability profile as the foundation of the platform is recycled copper and the technology is non-leaching. As a recognized micronutrient, copper presents a benign regulatory profile unlike other metal-ion (e.g. silver) or organic (e.g. ZnPT, PHMB, IPBC, etc.) alternatives under scrutiny in the marketplace.

Cupron Performance Additives is engaged with current sales and distribution partners to make the Cupron Sinerji technology platform available to their customers, and will add additional partners seeking to bring new additives to the commercial and industrial sectors.

 

Learn more here.

Recent News

04/02/2025

VCU startup wins $800k grant to propel its infection-fighting surgical gel

With an innovation that could advance brain and spinal surgeries, a Virginia Commonwealth University startup has received an $800,000 state grant to support development of its infection-fighting gel. Pascal Medical Corp. is one of four grant recipients to receive awards from Virginia Catalyst, a nonprofit created by the General Assembly and funded by the state’s general

04/02/2025

Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases, today announces additional highly positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome (NS) study. After 6 weeks of continued whole body application

04/02/2025

Charlottesville Angel Network Celebrates 10 Years, Surpasses $20 Million in Investments

The Charlottesville Angel Network (CAN), a group of accredited investors dedicated to supporting early-stage ventures, proudly marks its 10th anniversary this month. Since its inception, CAN angel investor members have invested more than $20 million in nearly 80 startups, fostering innovation both locally and beyond. Reflecting on a decade of achievements, CAN has realized returns